Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the P...
7000 Shoreline Court
South San Francisco, CA 94080
Founded in 2006
Veracyte, Inc. Appoints Tina S. Nova as Director and Chairman of the Regulatory and Compliance Committee
Nov 16 15
Effective November 12, 2015, the Board of Directors of Veracyte, Inc. elected Tina S. Nova, Ph.D. to the company's Board of Directors. In addition to serving on the Board of Directors, Dr. Nova will also serve as Chairman of the Regulatory and Compliance Committee of the Board of Directors. Dr. Nova, age 62, is a life sciences industry veteran with extensive experience building and leading novel genomics-based businesses. Since October 2015, she has served as president and chief executive officer of Molecular Stethoscope, Inc., a molecular diagnostics company.
Veracyte, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Reiterates Revenue Guidance for the Year 2015
Nov 5 15
Veracyte, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, revenue was $12.3 million, an increase of 25%, compared to $9.8 million for the third quarter of 2014. Net loss for the third quarter of 2015 was $8.9 million, or $0.32 per common share, versus a net loss of $7.9 million, or $0.37 per common share, for the same period in 2014. Loss from operations was $8,888,000 compared to $7,811,000 a year ago.
For the nine months, revenue was $35,461,000, compared to $25,991,000 for the same period in 2014. Loss from operations was $25,515,000 compared to $20,947,000 a year ago. Net loss was $25,691,000, or $1.01 per basic and diluted share compared to a net loss of $21,231,000 or $0.99 per basic and diluted share for the same period in 2014.
The company reiterated its 2015 annual revenue guidance of $48 million to $53 million.
Veracyte, Inc. to Report Q3, 2015 Results on Nov 05, 2015
Oct 29 15
Veracyte, Inc. announced that they will report Q3, 2015 results at 5:15 PM, US Eastern Standard Time on Nov 05, 2015